John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.
John P. Sfakianos, MD
Advertisement
Articles by John P. Sfakianos, MD
John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Treatment Selection in Advanced Prostate Cancer
3
Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA
4
Annual ACS NCDB report details national trends in prostate cancer care
5